# Pharmexcil

Type: Company

Source: GetYourBrief — https://getyourbrief.com/entity/pharmexcil
Canonical HTML page: https://getyourbrief.com/entity/pharmexcil

## Recent coverage (3 stories, network-wide)

### 200% Generic Drug Tariff Could Add $50B+ to US Healthcare Costs
2026-08-01 11:15:52 · Sector: health · Sentiment: Negative · Impact: 6/10 · Sources: 2

A proposed US tariff of up to 200% on generic drug imports threatens to sever the supply of affordable medicines from India, potentially causing shortages and billions in added costs for hospitals and patients. Industry experts warn that manufacturers cannot absorb the tariffs and may exit the US market, directly undermining efforts to control healthcare spending.
Full story: https://gethealthbrief.com/story/us-generic-drug-tariff-healthcare-costs-200-percent

### 200% US Tariff Threatens Indian Pharma's $50B+ US Generic Business
2026-08-01 11:15:43 · Sector: bio · Sentiment: Negative · Impact: 6/10 · Sources: 2

The proposed US tariff on generic drugs—jumping to 200%—poses an existential threat to Indian pharmaceutical companies that have long dominated the American market. With margins razor-thin and a 4-5 year timeline needed to onshore production, industry leaders call the plan 'completely out of scope,' potentially forcing a major restructuring of global generic supply chains.
Full story: https://getbiobrief.com/story/indian-pharma-us-generic-tariff-200-percent-existential-threat

### India-UK FTA Drives $981M Pharma Export Target, 8.66% Jump by FY27
2026-07-27 10:10:49 · Sector: bio · Sentiment: Positive · Impact: 6/10 · Sources: 2

The zero-tariff India-UK trade pact propels Indian pharmaceutical exports to a projected $981M, offering biotech and pharma firms expanded market access, lower costs, and new collaboration channels in R&D and manufacturing.
Full story: https://getbiobrief.com/story/india-uk-fta-pharma-exports-981-million-fy27

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.